SightfileU.S. market data from official filings

Companies › BBOT

BRIDGEBIO ONCOLOGY THERAPEUTIC (BBOT)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001869105 · EDGAR filings · Updated 2026-07-06

BRIDGEBIO ONCOLOGY THERAPEUTIC (BBOT) has reported institutional ownership of 71.8%, with 67 institutional managers holding positions valued at $513.8M per the latest 13F reporting period.

Institutional ownership
71.8%
Institutional managers
67
Reported 13F value
$513.8M
Insider activity
15 trans.
$0 net flat

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, BRIDGEBIO ONCOLOGY THERAPEUTIC has 67 institutional holders and institutional ownership of 71.8%.

Insider activity

Insiders reported 15 transactions (0 buys, 0 sells) across 9 reporting insiders, with a net reported value of $0.

Related companies

ZAI LAB LTD (ZLAB) · MYRIAD GENETICS INC (MYGN) · PRECIGEN (PGEN) · COMPASS PATHWAYS ADR A FUNSPONSORED ADR 1 ADR REPS 1 ORD SHS (CMPS) · MAPLIGHT THERAPEUTICS INC (MPLT) · BETA BIONICS INC (BBNX)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-06.